Process Development Senior Scientist – Drug Product Technologies
Amgen
- Location
- US - California - Thousand Oaks
- Work model
- On-Site
- Level
- Senior
- H-1B history
- 137 approvals (FY2023)
- Posted
- 21h ago
Skills
About this role
Career Category Operations Job Description Join Amgen’s Mission of Serving Patients At Amgen, if you feel like you’re part of something bigger, it’s because you are. Our shared mission—to serve patients living with serious illnesses—drives all that we do. Since 1980, we’ve helped pioneer the world of biotech in our fight against the world’s toughest diseases. With our focus on four therapeutic areas –Oncology, Inflammation, General Medicine, and Rare Disease– we reach millions of patients each year. Amgen is advancing a broad and deep pipeline of medicines to treat cancer, heart disease, inflammatory conditions, rare diseases, and obesity and obesity-related conditions. As a member of the Amgen team, you’ll help make a lasting impact on the lives of patients as we research, manufacture, and deliver innovative medicines to help people live longer, fuller happier lives. Our award-winning culture is collaborative, innovative, and science based. If you have a passion for challenges and the opportunities that lay within them, you’ll thrive as part of the Amgen team. Join us and transform the lives of patients while transforming your career. Process Development Senior Scientist – Drug Product Technologies What you will do Let’s do this. Let’s change the world. In this vital role you will bring hands-on experience in biologics drug product formulation, process development, and/or analytical characterization, with experience in ADCs and/or oligonucleotides such as siRNAs strongly preferred. The candidate will integrate formulation, analytical, stability, and process data to guide product design and development, including modality-specific considerations such as linker-payload attributes, stability- and process-relevant degradation pathways, ADC CQAs, oligonucleotide formulation and stability considerations, and phase-appropriate analytical strategies. This individual will apply scientific judgment, emerging technologies including AI/ML, and strong cross-functional collaboration to deliver high-quality, stable, and manufacturable drug products for clinical development in a fast-paced environment. Work effectively in a fast-paced, matrixed environment, collaborating across process development, research, analytical, regulatory, quality, manufacturing, and external partner teams to advance programs, influence development strategies, and communicate technical recommendations to scientific peers and leadership. Plan, lead, and execute formulation, stability, process development, and fill/finish studies for early-stage drug product programs across diverse biologic modalities. Develop and characterize liquid and lyophilized formulations for complex biologics, including ADCs, oligonucleotides, monoclonal antibodies, multispecifics, and other emerging modalities. Build process understanding across unit operations to support scalable drug product development. Evaluate in-use compatibility and drug product stability under clinically relevant conditions. Investigate biologics- and modality-relevant CQAs, including aggregation, fragmentation, charge and size variants, subvisible particles, surface interactions, concentration-dependent behavior, and, where applicable, ADC- or oligonucleotide-specific attributes such as drug-to-antibody ratio, free payload, linker-payload integrity, and oligonucleotide purity or degradation pathways. Leverage high-throughput and data-driven tools for formulation screening, stability assessment, developability evaluation, and processability characterization. Identify and address technology gaps impacting drug product stability, manufacturability, excipient interactions, modality-specific degradation pathways, and process-related stress responses. Apply machine learning, AI, automation, and data science approaches to predictive modeling, workflow acceleration, data integration, and decision-making. Ensure development approaches are phase-appropriate, from discovery through clinical